Trials / Completed
CompletedNCT03834623
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
A Phase II Biomarker Trial of Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune response).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-122 | Oral CC-122 at 2 mg daily, 5 days out of 7 |
| DRUG | Nivolumab | 240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle |
Timeline
- Start date
- 2019-05-14
- Primary completion
- 2021-06-29
- Completion
- 2021-08-04
- First posted
- 2019-02-08
- Last updated
- 2022-10-05
- Results posted
- 2022-09-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03834623. Inclusion in this directory is not an endorsement.